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Abstract
The aim of the present study was to investigate chromosomal aberrations in sporadic Japanese papillary thyroid carcinomas
(PTCs), concomitant with the analysis of oncogene mutational status. Twenty-five PTCs (11 with BRAF
V600E, 4 with RET/PTC1,
and 10 without mutation in HRAS, KRAS, NRAS, BRAF, RET/PTC1,o rRET/PTC3) were analyzed using Genome-Wide Human SNP
Array 6.0 which allows us to detect copy number alteration (CNA) and uniparental disomy (UPD), also referred to as copy
neutral loss of heterozygosity, in a single experiment. The Japanese PTCs showed relatively stable karyotypes. Seven cases
(28%) showed CNA(s), and 6 (24%) showed UPD(s). Interestingly, CNA and UPD were rarely overlapped in the same tumor;
the only one advanced case showed both CNA and UPD with a highly complex karyotype. Thirteen (52%) showed neither
CNA nor UPD. Regarding CNA, deletions tended to be more frequent than amplifications. The most frequent and recurrent
region was the deletion in chromosome 22; however, it was found in only 4 cases (16%). The degree of genomic instability
did not depend on the oncogene status. However, in oncogene-positive cases (BRAF
V600E and RET/PTC1), tumors with CNA/
UPD were less frequent (5/15, 33%), whereas tumors with CNA/UPD were more frequent in oncogene-negative cases (7/10,
70%), suggesting that chromosomal aberrations may play a role in the development of PTC, especially in oncogene-
negative tumors. These data suggest that Japanese PTCs may be classified into three distinct groups: CNA
+, UPD
+, and no
chromosomal aberrations. BRAF
V600E mutational status did not correlate with any parameters of chromosomal defects.
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Introduction
Papillary thyroid carcinoma (PTC) is the most common
malignant tumor in endocrine organs, and its incidence has
increased over the past decades [1]. PTCs have characteristic
genetic alterations leading to the activation of mitogen-activated
protein kinase (MAPK) signaling pathway. Those include RET/
PTC rearrangements and point mutations in BRAF and RAS family
genes [2]. They are found in approximately 60–70% of all PTCs
and rarely overlap in the same tumor [3–5]. The lack of
coexistence provides strong genetic evidence for the requirement
of constitutively active MAPK signaling for development of PTC.
However, the remaining 30–40% of PTC cases do not have
genetic changes in these genes, suggesting that other factors may
exist as a trigger to activate the MAPK pathway.
The BRAF mutation is the most prevalent genetic alteration in
PTCs (44% on average) [1]. The mutation in PTCs is almost
exclusively a thymine-to-adenine transversion at nucleotide 1799
in exon 15, resulting in a valine-to-glutamic acid substitution at
amino acid 600 (V600E) [1]. This mutation is believed to produce
a constitutively active kinase by disrupting hydrophobic interac-
tions between residues in the activation loop and residues in the
ATP binding site, allowing development of new interaction that
fold the kinase into a catalytically competent structure [6].
Many studies, but not all of them, have demonstrated the
associations between this mutation and clinicopathological aggres-
siveness such as extrathyroidal invasion, lymph node metastasis,
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36063advanced stage, and recurrence [1]. Indeed, transgenic mice
overexpressing BRAF
V600E in thyroid cells develop invasive PTCs
with some tall-cell features and poorly differentiated areas [7]. In
addition, conditional expression of BRAF
V600E in the rat normal
thyroid PCCL3 cells induced invasion and chromosomal in-
stability, which was not observed in the same system with RET/
PTC oncoprotein [8,9].
Chromosomal aberrations have been reported at relatively low
frequency in PTCs [10–17]. In these reports, comparative
genomic hybridization (CGH) which provides a low resolution
was used. However, two studies using array CGH, which enables
a higher resolution depending on the number of probes,
demonstrated a wide range of chromosomal aberrations [18,19].
In contrast to CGH or array CGH, single nucleotide poly-
morphism array (SNP-A) as a molecular karyotyping tool has
excellent resolution and allows us to detect copy number alteration
(CNA) and also uniparental disomy (UPD) in the same
experiment. The detection of UPD, also referred to as copy
neutral loss of heterozygosity (CN-LOH), along whole genome is
one of the advantages of SNP-A. The discovery of UPD in cancers
has indicated that LOH is not necessarily due to loss of
chromosomal material. In regions of UPD, portions of one of
the chromosomes are lost and replaced by the exact copy of the
other remaining chromosome, resulting in retention of two copies
of genetic information but loss of polymorphic differences (both
are from the same parent), which can be detected by SNP-A but
not by conventional cytogenetic analysis such as CGH. UPD has
been reported to be associated with both oncogenic mutations and
inactivation of tumor suppressor genes in cancers [20]. UPD may
be an important mechanism in cancer development [21,22]. To
the best of our knowledge, there has been only one study using
SNP-A for PTC; 10 cases of pediatric radiation-associated post-
Chernobyl PTCs were analyzed using Affymetrix 50 K Mapping
array [23]. However, no significant regions of LOH were
identified in this analysis. General sporadic PTCs have not been
analyzed using SNP-A.
In the present study, we analyzed 25 Japanese sporadic PTCs
with or without BRAF
V600E mutation using Affymetrix Genome-
Wide Human SNP Array 6.0 (SNP6.0) which gives much higher
resolution (1.8 M probes) compared to the previous studies. This is
the first report showing the presence of UPD in PTCs. We aimed
to assess whether BRAF mutational status is associated with
genomic instability and characteristic chromosomal aberrations
represented by CNA and UPD. We also attempted to identify
novel chromosomal portions that may contain genes involved in
PTC pathogenesis.
Materials and Methods
Patients and Tumor Tissues
Fresh tumor tissue samples were collected from 25 patients with
sporadic PTC (mean6SD age 53.3616.3 years old, range 18–
81 years old; 84.0% women; no any pretreatment), snap-frozen in
liquid nitrogen, and stored at 280uC until use. An appropriate
written informed consent was obtained from each patient, and the
study was approved by the ethics committees of Nagasaki
University and Kuma Hospital. All patients had no history of
radiation exposure. Clinical and pathological characteristics of the
patients including UICC TNM staging are listed in Table 1.
Among 25 PTC samples, 11 had BRAF
V600E mutation, 4 had
RET/PTC1 rearrangement, and 10 did not have any of the
following oncogenic alterations: HRAS, KRAS, NRAS, and BRAF
mutations; and RET/PTC1 and RET/PTC3 rearrangements. In
this study, no new sequence data was generated.
Genomic DNA Extraction and Mutation Screening for
BRAF and RAS
DNA was extracted from the frozen tissues using QIAamp DNA
mini kit (QIAGEN, Tokyo, Japan) according to the manufac-
turer’s protocol. Common mutational hotspots of BRAF (exon 15)
and HRAS, KRAS and NRAS (codons 12, 13, and 61) were
examined by direct DNA sequencing. Primer sequences used for
PCR and sequencing are listed in Table S1. PCR amplification
was done using AmpliTaq Gold (Applied Biosystems, Life
Technologies Japan, Tokyo, Japan). PCR products were treated
with ExoSAP-IT PCR clean-up reagent (GE Healthcare Japan,
Tokyo, Japan), and sequencing was performed with Big Dye
Terminator sequencing kit version 3.1 (Applied Biosystems) on an
ABI3100 automated sequencer (Applied Biosystems).
RET/PTC Rearrangement Screening
For RET/PTC screening, RNA extraction and RT-PCR were
done. Briefly, total RNA was extracted from the frozen tissues
using ISOGEN (Nippon Gene, Tokyo, Japan) reagent according
to the manufacturer’s instruction. The RNA was then reverse
transcribed using MMLV-RT (Applied Biosystems) and random
hexamers to generate cDNA. Subsequent PCR amplification was
performed using AmpliTaq Gold. Primer sequences are listed in
Table S1.
Copy Number Detection and SNP Genotyping by High
Resolution Genome-wide DNA Microarray
We performed high-resolution genome-wide DNA copy num-
ber detection and single nucleotide polymorphism (SNP) genotyp-
ing using Genome-Wide Human SNP Array 6.0 (SNP6.0) that
interrogates 906,600 SNPs and 945,826 copy number probes,
following the manufacturer’s instructions (Affymetrix Japan,
Tokyo, Japan). Array scanning and genotyping were performed
using Affymetrix GeneChip Command Console (AGCC) and
Birdseed v2 algorithm of Genotyping Console (GTC) 4.0 software
(Affymetrix). As a quality control of the genotyping, Contrast QC
value was calculated as implemented in the GTC 4.0. Genomic
positions of the SNPs corresponded to the March 2006 human
genome (hg18). Copy number and allele ratio analysis was
performed by Partek Genomics Suite version 6.5 (Partek Inc.,
St. Louis, MO, USA). Reference generated from the intensities of
pooled 52 normal Japanese sample profiles in our laboratory was
used. The data sets were also used as a baseline to determine
LOH. Genomic segmentation method was used to detect
amplified or deleted segments using Partek Genomics Suite with
stringent parameters (p#0.0001, $20 markers, signal/noise
$0.6), and only segments $100 probes were considered for
further analysis to avoid false positive [24].
UPD areas were also confirmed using Hidden Markov Model
and Copy Number Analyser for GeneChip 3.0/Allele-specific
Copy Number Analysis using anonymous References (CNAG/
AsCNAR) as previously described (compared with 3–10 best fit
normal references with the lowest SD) [25,26]. Copy number
variations (CNVs) seen in both our SNP6.0 analysis and the
Database of Genomic Variants (DGV, http://projects.tcag.ca/
variation/) were considered as tumor-unrelated CNVs and
excluded from further analysis [27]. When run of homozygosity
(ROH) was detected, telomeric lesions or interstitial defects
$24.6 mega bases (Mb) were considered true acquired somatic
UPD (AS-UPD), since small region of homozygosity can result
from autozygosity or germline UPD [27–29]. In a strict sense,
however, AS-UPD (or CN-LOH) can only be confirmed by
comparing tumor tissue with non-tumor tissue in one individual.
CNA and UPD in the Japanese PTCs
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e36063Accordingly, the term ‘‘UPD’’ used in this study is rigorously equal
to a relatively large segment region of ROH, although it is most
likely AS-UPD.
Regions of CNA or UPD were cross-referenced with Refseq
genes (http://www.ncbi.nlm.nih.gov/RefSeq/) and the Cancer-
Gene database (http://cbio.mskcc.org/CancerGenes/Select.
action) [30].
Comparison of Genomic Instability and Statistical
Analysis
To estimate genomic instability, the length of each genomic
alteration (CNA and UPD) was summed, and the total length was
divided by 2,858,034,764 bases, which is the total length of human
genome (hg18), to calculate the percentage of altered genome.
Differences between groups divided by the status of oncogenic
mutations were examined for statistical significance with Kruskal-
Wallis test.
Odds ratios and 95% confidence intervals for the association
between the presence of chromosomal aberration(s) and clinico-
pathological parameters including BRAF mutational status were
estimated using unconditional logistic regression models including
age, tumor size, histological type, and stage.
Results
CNA and UPD in the Japanese PTCs
We analyzed genomic DNA from 25 Japanese PTC tissues by
SNP6.0. A genome-wide view of detected CNA and UPD is shown
in Figure 1 and summarized in Table S2. UPDs .10 Mb and
,24.6 Mb were also included for reference although we cannot
exclude the possibility that these UPDs are germline. However, all
these short UPDs were observed along with long UPDs
($24.6 Mb) in all the cases except one (T15, Figure 1b), suggesting
that most of these short UPDs are likely to be acquired somatic
UPD (AS-UPD) (see Materials and Methods section). Neverthe-
less, the short UPDs were excluded from the further analyses due
to uncertainty.
Japanese PTC samples are very heterogeneous concerning the
number, size, and location of CNA/UPD. The majority of the
cases showed a few or no CNA/UPD (Figure 1b), and
interestingly, CNA and UPD were rarely overlapped in the same
tumor. Seven cases (T17, T19, T21, T32, T36, T48, T50; 28%)
showed CNA(s), and 6 (T05, T06, T07, T13, T17, T23; 24%)
showed UPD(s) (Table S2, Figure S1, and S2). Only one case
(T17; 4%) showed both CNA and UPD with a highly complex
karyotype (Table S2 and Figure S1). Thirteen (T08, T11, T15,
T18, T20, T24, T25, T27, T30, T45, T47, T53, T58; 52%)
showed neither CNA nor UPD. Regarding CNA, deletions tended
to be more frequent than amplifications (Figure 1). Associations
between CNA (deletion and amplification)/UPD and clinicopath-
ological parameters including BRAF mutational status were
estimated using unconditional logistic regression models. Only
follicular variant (fv) histotype (vs. classic papillary) was weakly
associated with deletion (Odds ratio=15.6, 95% confidence
interval: 0.75–795.4, p=0.098) but note that only three fv cases
were included in our analysis. No obvious correlation was found
between chromosomal aberrations and any other parameters
(Table 1).
Comparison of the Japanese PTCs by the Status of
Oncogenic Mutation
CNA occurred in 2 PTCs with BRAF
V600E (2/11, 18%), 1 with
RET/PTC1 (1/4, 25%), and 4 without oncogenic mutation (no
HRAS, NRAS, KRAS, BRAF
V600E, RET/PTC1, RET/PTC3) (4/10,
40%) (Figure 1 and Table 1). The most frequent and recurrent
CNA was the deletion in chromosome 22; however, it was found
in only 4 cases (4/25, 16%): 2 PTCs with BRAF
V600E, 1 with RET/
PTC1, and 1 with no mutation (Figure 1). No specific CNA was
found in each oncogene group (Figure 1).
UPD was found in 3 PTCs with BRAF
V600E (3/11, 27%) and in
3 with no mutation (3/10, 30%) (Figure 1 and Table 1). We found
11 interstitial UPDs (range, 24.6–105.7 Mb) and 1 UPD extend-
ing to the telomere. These UPDs were not overlapped, except for
small regions on chromosome 12q (T23 and T05) (Figure 1 and
Figure S2).
Interestingly, in oncogene-positive cases (BRAF
V600E and RET/
PTC1), tumors with CNA/UPD were less frequent (5/15, 33%),
whereas tumors with CNA/UPD were more frequent in
oncogene-negative cases (7/10, 70%).
Next, we also measured the degree of genomic instability using
the percentage of altered genome (Table 1). As shown in Figure 2,
there was no statistical difference among three oncogene groups
(no mutation, BRAF
V600E, and RET/PTC1).
Candidate Genes Involved in the Japanese PTC
Pathogenesis
To find important tumorigenic events in PTC, we searched for
CNA/UPD that was commonly shared among the samples. As
mentioned above, the only recurrent genomic aberration was the
deletion on chromosome 22q in 4 samples (4/25, 16%), which was
independent of the oncogene status (Figure 1). The 22q deletion
was large, spanning a 34 Mb region and containing 66 genes
registered at the CancerGenes database (Table S3), some of which
are potential tumor suppressor genes (TOP3B, CHEK2, NF2, LIF,
DUSP18, TIMP3, XRCC6, and PPARA).
Since constitutive activation of the MAPK pathway is thought
to be critical for PTC development, we next searched for RAS
family/MAPK pathway genes (at CancerGenes) and also PTC-
related genes reported in literature within CNA/UPD regions,
regardless of their frequency. Selected candidate genes are listed in
Table S4.
Discussion
In the present study, we have performed SNP6.0 analyses using
the Japanese PTC tissue samples. As far as we know, this is the first
report using SNP6.0 for molecular karyotyping of PTCs and also
demonstrating the occurrence of UPD. SNP6.0 contains 1.8 M
probes and achieves ultra high resolution (1 copy number marker
every 700 bp on average). Since this study is unpaired analysis, we
used stringent parameters to avoid false positive and also the
CNAG/AsCNAR algorithm (see Materials and Methods section)
which enables accurate determination of allele-specific copy
number without using paired normal DNA as well as the sensitive
detection of LOH (including UPD) even in the presence of up to
70–80% of normal cell contamination. Moreover, we also utilized
public copy number variation (CNV) database because CNVs are
common in a wide range of human individual genome, covering
1002 Mb(35%ofthegenome)(http://projects.tcag.ca/variation/).
Indeed, we excluded most of the small regions that were
overlapped with the CNVs in the database. We believe that we
avoided false positive but probably had false negative areas,
although they were small regions.
Of 25 PTC cases, our data demonstrate relatively stable
karyotypes: 7 CNAs, 6 UPDs (one case has both CNAs and
UPD), and 13 normal karyotypes, consistent with earlier studies
using conventional CGH or low resolution array CGH [10–17].
However, two recent studies using higher resolution array CGH
CNA and UPD in the Japanese PTCs
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e36063and SNP-A reported chromosomal aberrations in all analyzed
samples [18,23]. Although CNV was not taken into consideration
in these analyses, there were obvious differences among 3 studies
including ours. Unger et al. demonstrated nearly whole loss of
chromosome 17, 19, and 22 in most of adult RET/PTC-negative
cases, which is not consistent with our data, and also loss of
chromosome 6, 9p, and 13 in childhood cases, which is not
matched to the study by Stein et al. We do not have any feasible
explanation to solve this discrepancy. This might be due to ethnic
variations.
Figure 1. Genome-wide view of detected CNA and UPD. Twenty-five PTCs (11 with BRAF
V600E, 4 with RET/PTC1, and 10 without mutation in
HRAS, KRAS, NRAS, BRAF, RET/PTC1,o rRET/PTC3) were analyzed using Genome-Wide Human SNP Array 6.0. Green lines: amplifications, red lines:
deletions, blue lines: large ($24.6 Mb) interstitial UPD regions, gray lines: small interstitial UPD regions (at least 10 Mb but no more than 24.6 Mb),
orange lines: telomeric regions of UPD. a, Chromosomal view. Each line represents an individual aberration. The extent of the aberration is
represented along the length of the chromosome. b, Case (oncogene status)-chromosome plot, which provides at-a-glance view of all aberrations in
a single case. The extent of the aberrations is ignored.
doi:10.1371/journal.pone.0036063.g001
CNA and UPD in the Japanese PTCs
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e36063Japanese PTCs have some distinct characteristics: the vast
majority are low risk tumors with classic papillary morphology and
higher prevalence of the BRAF mutation than in PTCs in western
countries [31–34]. These characteristics are presumably due to
high iodine intake in Japanese population [35–37]. There have
been a large number of publications reporting the relationship
between BRAF
V600E mutation and clinicopathological aggressive-
ness (reviewed in [1]). In vivo and in vitro studies have also indicated
that BRAF
V600E drives aggressiveness and genomic instability [8,9].
However, a recent study analyzing more than 600 Japanese
patients in a single institution has demonstrated extremely good
prognosis and no correlation of the BRAF mutational status with
clinicopathological aggressiveness [38]. This is in line with our
results: low prevalence of CNA/UPD and no relationship between
BRAF status and genomic instability in the Japanese PTCs.
Further studies using samples from different ethnicities are needed.
It is of great interest that CNA and UPD were rarely overlapped
in the same tumor. Five tumors with UPD had no CNA; six
tumors with CNA had no UPD; only one tumor, T17 had both
CNA and UPD. T17 was the only case with distant metastasis
(lung), prominent vascular invasion, and recurrence. Along with
highly complicated genomic aberrations, T17 is the end stage of
the disease and may be exceptional. Thus, Japanese PTCs may be
classified into three distinct groups: CNA
+, UPD
+, and no
chromosomal aberrations, suggesting that different ways of
acquiring genomic instability exist in PTCs. The frequency of
CNA/UPD was higher in oncogene-negative cases (70%) than in
oncogene-positive cases (33%), suggesting that chromosomal
aberrations (or affected gene sets) may play a role in the
development of PTC, especially in oncogene-negative tumors,
albeit not statistically significant (Fisher’s exact test, odds
ratio=4.667, 95% confidence interval: 0.83–26.25, p=0.11).
This implies that there may be distinct mechanisms for PTC
development through oncogenic mutation and/or chromosomal
instability.
We tried to identify novel chromosomal regions/genes involved
in PTC pathogenesis, depending on mutational status of the
oncogenes. However, the pattern of CNA/UPD in the Japanese
cases was very heterogenous. We only found the 22q deletion as
a recurrent region, which is consistent with previous studies [12–
17]. However, the 22q deletion was found in only 4 cases,
suggesting that it may be difficult to find specific chromosomal
aberrations that contain responsible genes for PTC development
even though SNP6.0 was utilized. Furthermore, the presence of
the 22q deletion was independent of the oncogene status. We
selected candidate genes from the 22q area and other CNA/UPD
regions using the CancerGenes database. Among the selected
genes in the 22q area, CHEK2 [39], LIMK2 [40], and TIMP3 [41]
have already been reported to be deleted/down-regulated in
thyroid cancer; the 22q deletion may play a role in thyroid
carcinogenesis. Regarding the selected genes in other CNA/UPD
areas, the AKT3/PIK3CA pathway [42,43], the KRAS/RAP1B/
RAP1GAP/BRAF pathway [44,45], and the VEGFC pathway
[46,47] have been known to participate in thyroid carcinogene-
sis/cancer progression. However, none of them is universal in
PTCs.
In conclusion, we report for the first time the results of genome-
wide molecular karyotyping using SNP6.0 concomitant with the
analysis of oncogene mutational status in PTCs. The Japanese
PTCs showed relatively stable karyotypes: approximately 1/4 of
CNA, 1/4 of UPD, and 1/2 of no aberrations. We also
demonstrate for the first time that UPD as a form of genomic
instability may play a role in PTC development.
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Figure 2. The degree of genomic instability among three
oncogene groups (wild-type, BRAF
V600E, and RET/PTC1). Each dot
represents the percentage of altered genome of each case. The length
of each genomic alteration (CNA/UPD) was summed, and the total
length was divided by 2,858,034,764 bases to calculate the percentage
of altered genome. Horizontal line shows mean. T17 case had a highly
complex karyotype and was the only case with distant metastasis/
recurrence. There was no statistical difference among these groups.
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